Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)
Clinical trial NCT02180061 · COMPLETED
Trial details
- NCT number
- NCT02180061
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-15
- Primary completion
- 2017-08-31
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.